A study reviewed the role of microbiota in psoriasis pathogenesis and the potential of integrating microbiota-modifying strategies with current pharmacological treatments. The review highlights psoriasis’s association with cardiovascular comorbidities, evidenced by elevated inflammatory biomarkers and endothelial dysfunction in patients, a precursor to atherosclerosis. This link is reinforced by studies showing chronic skin inflammation’s role in vascular inflammation. The study also notes a decrease in microbial diversity in psoriatic lesions and explores the gut-skin axis, showing intestinal microbiota changes in psoriasis patients can lead to other inflammatory conditions. The potential of probiotics and next-generation probiotics as treatments for psoriasis and its cardiovascular comorbidities is discussed, along with the challenges and prospects of microbial modifying therapies in managing psoriasis and related health issues.
Reference: Reali E, Caliceti C, Lorenzini A, et al. The Use of Microbial Modifying Therapies to Prevent Psoriasis Exacerbation and Associated Cardiovascular Comorbidity. Inflammation. 2024 Feb;47(1):13-29. doi: 10.1007/s10753-023-01915-1. Epub 2023 Nov 13. PMID: 37953417; PMCID: PMC10799147.
